Celltrion Reports Submission of a Marketing Application to Health Canada for CT-P39 for all Originator Indications
Shots:
- The application was submitted based on the results from the P-III clinical trial evaluating the safety & efficacy of CT-P39 vs Xolair in patients (n=619) with chronic spontaneous urticaria (CSU) across 6 EU countries
- Results from the study supporting filling with Health Canada to gain approval for all approved indications of Xolair (Incl. allergic asthma, chronic rhinosinusitis & chronic urticaria)
- The originator of CT-P39, Xolair is an antibody developed jointly by Genentech and Novartis. XOLAIR's material patent has expired, Whereas, formulation patent expires in Mar 2024 in EU & Nov 2025 in the US
Ref: The Bio | Image: Celltrion
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
